August 21-23, 2018

Boston, MA


  • A Microvascularized Tumor-mimetic Platform for Assessing Anti-cancer Drug Efficacy

    This exciting paper presents a chip-based tumor-mimetic platform incorporating a 3D in vitro breast cancer model with a tumor-mimetic microvascular network, replicating the pathophysiological architecture of native vascularized breast tumors.

  • Exclusive Interview with MIT

    Murat Cirit – Director of Systems Pharmacology, Translational Center of Tissue Chip Technologies (TC²T) at MIT – discusses how computational models such as quantitative systems pharmacology (QSP) can be applied to enhance the design and development of advanced in vitro platforms.

    Our vision is to generate physiologically relevant information with the use of the all human 3D models, which can be translated to human outcomes

    Joining as a workshop leader this year, he said: 

    I am looking forward to gaining more insight into academic developments and how they are pushing forward our research and translational approach, while learning the industrial needs from many leaders in this MPS field.

  • Past Presentations Pack

    Contains the following presentations from 3D Tissue Models 2016:

    1) Creating the Environment to Drive Innovation: The Roadmap to Acceptance

    • By Donna L. Mendrick,  Associate Director for Regulatory Activities, FDA/NCTR

    2) Use of 3D Tissue Models for Pre-Animal Screening and to Improve Clinical Translation

    • By Brian R. Berridge, Director & Head WW Animal Research Strategy, GlaxoSmithKline

  • Interview with Chief Scientific Officer at Organovo

    Read about Organovo’s journey and the rise of 3D Bioprinting technology, the remaining challenges in shifting the paradigm of drug development as well the next key focus areas for them.

    “I believe we are on the cusp of tackling the discovery applications that will take us far beyond the basic biology and toxicology”